HT treatment with estrogens alone or in combination with progestogens was associated with a small to moderate improvement in sexual function , particularly in pain , when used in women with menopausal symptoms or in early postmenopause ( within five years of amenorrhoea ) , but not in unselected postmenopausal women .
The current evidence does not suggest an important effect of tibolone or of SERMs alone or combined with estrogens on sexual function .
BACKGROUND The perimenopausal and postmenopausal periods are associated with many symptoms , including sexual complaints .
OBJECTIVES To assess the effect of hormone therapy ( HT ) on  sexual function in perimenopausal and postmenopausal women .
A randomized study of low-dose conjugated estrogens on sexual function and quality of life in postmenopausal women
Objective : To evaluate the effects of combined vaginal and oral low-dose estrogen plus progestogen therapy ( EPT ) on the frequency and severity of dyspareunia , sexual function , and quality of life in recently postmenopausal women . Methods : This outpatient , double-blind , r and omized , placebo-controlled trial enrolled 285 healthy , sexually active postmenopausal women aged 45 to 65 years . Women received either one daily oral low-dose conjugated estrogens ( 0.45 mg)/medroxyprogesterone ( 1.5 mg ) tablet for six 28-day cycles along with 1 g conjugated estrogens vaginal cream ( 0.625 mg ) , intravaginally for the first 6 weeks of the trial or a placebo cream and placebo tablet .  Efficacy was evaluated using the McCoy Female Sexuality Question naire , self-reported daily diary cards , the Brief Index of Sexual Functioning-Women ( BISF-W ) , and the Women 's Health Question naire . Results : The EPT group had a significant decrease in the frequency of dyspareunia compared with baseline and placebo in an analysis of responses to the McCoy Female Sexuality Question naire . Also , EPT was associated with a significant improvement in a woman 's level of sexual interest , frequency of orgasm , and pleasure of orgasm . There was no effect of EPT use on coital frequency . The EPT group had significant improvement in receptivity/initiation and relationship satisfaction , although not in other BISF-W domains , versus placebo ( BISF-W analysis ) and significant improvement versus placebo on most Women 's Health Question naire responses . Conclusions : EPT provided a statistically significant improvement compared with placebo in dyspareunia , sexual experience , and quality of life as measured in this study . In general , EPT also improved self-reported sexual perception and enjoyment significantly compared with placebo
HT treatment with estrogens alone or in combination with progestogens was associated with a small to moderate improvement in sexual function , particularly in pain , when used in women with menopausal symptoms or in early postmenopause ( within five years of amenorrhoea ) , but not in unselected postmenopausal women .
The current evidence does not suggest an important effect of tibolone or of SERMs alone or combined with estrogens on sexual function .
BACKGROUND The perimenopausal and postmenopausal periods are associated with many symptoms , including sexual complaints .
OBJECTIVES To assess the effect of hormone therapy ( HT ) on  sexual function in perimenopausal and postmenopausal women .